

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 37 (Cancelled)

Claim 38. (New) A composition for the inhibition of heparanase glycosidase catalytic activity, consisting essentially of, as a first constituent, a pharmaceutically acceptable material selected from the group consisting of a carrier, a diluent, an excipient and an additive, and, as a second constituent one of eosinophil cell lysate, eosinophil secondary granules basic protein, poly-L-arginine and mixtures thereof, wherein the second constituent is present in a concentration of about 1 to about 180 µg/ml.

Claim 39. (New) A composition according to claim 38, wherein the eosinophil secondary granules basic protein is selected from the group consisting of the 117 amino acid residue of MBP (Major Basic Protein), ECP (Eosinophil Cationic Protein), EPO (Eosinophil Peroxidase) and EDN (Eosinophil Derived Neurotoxin).

Claim 40. (New) A composition according to claim 39, wherein the eosinophil secondary granules basic protein is the 117 amino acid residue of MBP (Major Basic Protein).

Claim 41. (New) A composition according to claim 39, wherein said eosinophil secondary granules basic protein is provided as one of a purified recombinant protein, a fusion protein, a nucleic acid construct encoding for said protein, a host cell expressing said construct, a cell, a cell line, tissue endogenously expressing said protein and a lysate thereof.

Claim 42. (New) A method for the inhibition of heparanase glycosidase catalytic activity in a subject consisting essentially of the step of administering to the subject one of eosinophil cell lysate, an eosinophil secondary granules basic protein and mixtures thereof in a concentration of from about 1 to about 180 μ g/ml.

Claim 43. (New) The method according to claim 42, wherein the eosinophil secondary granules basic protein is selected from the group consisting of the 117 amino acid residue of MBP (Major Basic Protein), ECP (Eosinophil Cationic Protein), EPO (Eosinophil Peroxidase) and EDN (Eosinophil Derived Neurotoxin).

Claim 44. (New) The method according to claim 43, wherein the eosinophil secondary granules basic protein is the 117 amino acid residue of MBP (Major Basic Protein).

Claim 45. (New) The method according to claim 43, wherein the eosinophil secondary granules basic protein is provided as any one of a purified recombinant protein, a fusion protein, a nucleic acid construct encoding for said protein, a host cell expressing said construct, a cell, a cell line and a tissue endogenously expressing said protein or a lysate thereof.

Claim 46. (New) Method for preparation of a composition for the inhibition of heparanase glycosidase catalytic activity consisting essentially of the step of formulating a first constituent composed of a pharmaceutically acceptable material selected from the group counting of a carrier, a diluent, an excipient and an additive with a second constituent composed of one of eosinophil cell lysate, an eosinophil secondary granules basic protein, and mixtures thereof in a concentration of from about 1 to about 180 μ g/ml.

Claim 47. (New) The method according to claim 46, wherein the eosinophil secondary granules basic protein is 117 amino acid residue of MBP (Major Basic Protein).

48. Claim (New) The method according to claim 46, wherein the eosinophil secondary granules basic protein is one of a purified recombinant protein, a fusion protein, a nucleic acid construct encoding for said protein, a host cell expressing said construct, a cell, a cell line, a tissue endogenously expressing said protein and a lysate thereof.

Claim 49. (New) A method for the inhibition of heparanase glycosidase catalytic activity consisting essentially of the step of contacting cells having heparanase glycosidase catalytic activity with one of eosinophil cell lysate, an eosinophil secondary granules basic protein and mixtures thereof in a concentration of from about 1 to about 180 µg/ml.